arrow_back HD Research Hub

Deep Full-Text Analysis of 16 HD Papers

Experiment #2 | March 30, 2026

Experiment Card

ID
EXP-002
Date
2026-03-30T09:00:00Z
Type
Full-Text Deep Analysis (not abstracts)
Status
Complete
Hypothesis
Reading full papers (Methods, Results, Discussion) produces deeper insights than abstracts alone
Outcome
Confirmed. Found targets (cGAS, DNJC7, LIG1) and contradictions not visible from abstracts.
Scale
Papers: 16 (full text)
Sections: 380
Characters: 1,935,627
vs Exp #1: 440x more text
Infrastructure
Model: Llama 3.1 8B
Context: 64K tokens
Hardware: Jetson AGX Orin 64GB
Cost: $0
What Changed

Experiment #1 read abstracts (200 words each). This experiment read entire papers end-to-end: Introduction, Methods, Results, Discussion, Conclusions. 1.9 million characters vs 4,400.

Top Findings

LIG1 K845N variant suppresses somatic CAG expansion

The K845N variant of DNA Ligase 1 confers enhanced substrate discrimination and increased repair fidelity, suppressing somatic CAG expansion in mouse models. This was only visible in the full Methods and Results sections.

CRISPR-Cas for precise HD genetic modification

Multiple papers confirm CRISPR technology can address the underlying genetic cause of HD, not just symptoms. Detailed protocols and in-vivo results were in the full text, absent from abstracts.

Mitochondrial dysfunction drives neuroinflammation across HD, AD, PD

Cross-disease pattern: mitochondrial DNA release triggers cGAS-STING pathway, causing neuroinflammation. This connection appeared in 3 papers and only became clear from reading the Discussion sections.

New Hypotheses (from full-text analysis)

cGAS-STING Pathway

cGAS mtDNA Inhibition

Confidence90/100

Inhibiting cGAS-mediated mitochondrial DNA release may reduce neuroinflammation across HD, AD, and PD. Found in 3 papers' Discussion sections.

DNA Repair

LIG1 K845N Target

Confidence80/100

The LIG1 K845N variant suppresses somatic CAG expansion and improves mitochondrial function. Potential therapeutic target for HD.

Gene Therapy

CRISPR Mito Delivery

Confidence70/100

CRISPR-Cas could deliver genes promoting mitochondrial biogenesis and function in neurodegenerative disease.

Promising Targets (from full text)

Target Papers Why Promising
HTT CAG repeat4Root cause. Multiple therapeutic approaches targeting it directly.
cGAS3Mediates mtDNA-driven neuroinflammation. Cross-disease target (HD, AD, PD).
DNJC72Potent modifier of polyQ protein aggregation.
LIG11K845N variant suppresses somatic expansion. Novel finding from full text.

Contradictions Found

No clear consensus on the role of copper homeostasis imbalance in neurodegenerative diseases. Some papers suggest it contributes to disease progression. Others don't mention it. This disagreement was only visible from reading full Discussion sections.

Gaps Identified

Gut microbiota dysbiosis in HD is poorly understood and barely studied.

Limited CRISPR-Cas research in human HD subjects. Most data is from animal models.

warning

Limitations

  • Only open-access papers (paywalled papers excluded)
  • Single model (Llama 3.1 8B), single run
  • Not reviewed by HD domain experts
  • Context window limited very long papers
  • AI-generated hypotheses are unvalidated starting points

Methodology

01

Data

Full text from PubMed Central (open access only)

02

Model

Llama 3.1 8B, 64K context, Ollama on Jetson AGX Orin

03

Analysis

Each full paper sent to LLM. Deep extraction + cross-paper synthesis.

Read Experiment #1 (abstracts) | Research Tracker | Dashboard